novo nordisk glp 1 agonist EMA will monitor suicide risk in Nordisk's GLP-1 products Administration Anounces Landmark GLP-1 Pricing
Description
Public Citizen contends that Novo Nordisk and Eli Lilly's obesity drugs are straining budgets so much that generics should be authorized.
As fatty liver disease continues to drive downstream costs, this signal is getting serious attention
#thirdcause
Ozempic has become a buzzword in weight loss and type 2 diabetes management
Could it be because Indian physicians are conservative when it comes to prescribing newer drugs
Appetite and craving support
